BioTech IP Review

Assignee: Neuronetics, Inc.
Patent Number: US 12,394,512
Filed: May 10, 2024
Issued: August 19, 2025
Inventors: Neeraj Mainkar, Ravi Pillutla, Kenneth Marc Ghiron, Mark Edward Riehl 

What This Patent Covers

This patent protects methods and systems for generating a precise three‑dimensional head model of a patient for use in therapeutic or diagnostic procedures — especially non‑invasive brain stimulation like TMS. The technology enables a treatment system to:

• Use sensors (e.g., IR or optical) to capture a plurality of points on a subject’s head, including facial feature information.
• Combine those points with a predetermined head model to create a fitted head model that reflects the individual’s unique anatomy.
• Determine anatomical landmarks (such as nasion, inion, motor threshold points) and compute treatment target locations without requiring additional imaging like MRI or CT.
• Visualize the fitted head model and target locations to guide a technician during therapy setup and execution (e.g., coil placement for TMS).
• Save and recall the head model for use in subsequent sessions or diagnostic procedures. 

In simpler terms, this patent covers software and hardware processes that let a TMS system quickly build an accurate head map tailored to the patient — improving the positioning, consistency, and personalization of neurostimulation treatments without the need for complex imaging. 

---

Why This Is Important

• Drives core product differentiation: Neuronetics’ flagship NeuroStar Advanced Therapy System — used to treat major depressive disorder and other neuropsychiatric conditions — relies on precise TMS targeting. A personalized head model enhances treatment accuracy and outcomes. 
• Improves clinical adoption: Clinicians are more likely to adopt systems that simplify setup and increase treatment precision, strengthening NeuroStar’s competitive position.
• Strengthens IP moat: This patent adds proprietary technology around patient‑specific neurostimulation workflows, making it harder for competitors to replicate without infringing.
• Supports future innovation: Accurate modeling technology can be extended to new neuromodulation devices, diagnostic tools, or AI‑assisted treatment planning, broadening Neuronetics’ product roadmap.
• Investment and customer confidence: Issuance of patents like this helps reinforce the company’s long‑term strategy around intellectual property supporting non‑drug brain therapies.